PALFORZIA
Biological
AIMMUNE THERAPEUTICS, INC.
Total Payments
$8.6M
Transactions
8,076
Doctors
2,285
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $14,010 | 89 | 88 |
| 2023 | $48,845 | 263 | 215 |
| 2022 | $1.8M | 3,324 | 1,501 |
| 2021 | $3.0M | 2,628 | 912 |
| 2020 | $3.8M | 1,772 | 479 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $7.7M | 2,669 | 89.6% |
| Honoraria | $370,607 | 439 | 4.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $267,966 | 87 | 3.1% |
| Food and Beverage | $97,961 | 4,491 | 1.1% |
| Consulting Fee | $95,707 | 27 | 1.1% |
| Travel and Lodging | $39,178 | 116 | 0.5% |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,000 | 2 | 0.2% |
| Education | $7,703 | 245 | 0.1% |
Payments by Type
Research
$7.7M
2,669 transactions
General
$892,121
5,407 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY | AIMMUNE THERAPEUTICS, INC. | $5.0M | 0 |
| PEANUT ORAL IMMUNOTHERAPY STUDY OF EARLY INTERVENTION FOR DESENSITIZATION (POSEIDON) | AIMMUNE THERAPEUTICS, INC. | $2.0M | 0 |
| PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY | AIMMUNE THERAPEUTICS, INC. | $306,106 | 0 |
| REAL-WORLD AR101 MARKET-SUPPORTING EXPERIENCE STUDY IN PEANUT-ALLERGIC CHILDREN, ACTIVE TREATMENT ARM OPEN-LABEL EXTENSION STUDY (RAMSES OLE) | AIMMUNE THERAPEUTICS, INC. | $175,904 | 0 |
| A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY | Aimmune Therapeutics, Inc. | $143,755 | 0 |
| SAFETY OF CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY (CODITTM) WITH AR101 IN PEANUT-ALLERGIC CHILDREN AND ADULTS (RAMSES) | AIMMUNE THERAPEUTICS, INC. | $17,748 | 0 |
Top Doctors Receiving Payments for PALFORZIA — Page 2
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D., | Pediatric Allergy/Immunology | Miami Lakes, FL | $9,959 | 13 |
| , MD | Allergy | Colorado Springs, CO | $8,812 | 15 |
| , M.D | Pediatrics | Nashville, TN | $8,444 | 12 |
| , M.D | Allergy & Immunology | Louisville, KY | $8,438 | 2 |
| , MD | Specialist | Denver, CO | $8,371 | 12 |
| , M.D | Allergy | Sarasota, FL | $8,023 | 3 |
| , MD | Allergy & Immunology | Walnut Creek, CA | $7,254 | 3 |
| , MD | Allergy & Immunology | Cincinnati, OH | $7,250 | 2 |
| , M.D | Allergy | Rolling Hills Estates, CA | $7,188 | 2 |
| , M.D | Internal Medicine | Tucson, AZ | $7,188 | 1 |
| , MD | Internal Medicine | Mission Viejo, CA | $7,188 | 1 |
| , M.D | Pediatric Allergy/Immunology | New York, NY | $7,183 | 3 |
| , MD | Pediatric Allergy/Immunology | Atlanta, GA | $6,063 | 11 |
| , MD, PHD | Allergy & Immunology | Dallas, TX | $5,180 | 6 |
| , MD | Allergy & Immunology | Houston, TX | $4,627 | 5 |
| , M.D | Internal Medicine | Bellingham, WA | $4,594 | 5 |
| , MD PHD | Pediatric Allergy/Immunology | Houston, TX | $4,075 | 2 |
| , MD | Pediatric Allergy/Immunology | Little Rock, AR | $3,708 | 2 |
| , MD | Allergy & Immunology | West Hartford, CT | $3,491 | 5 |
| , RN, MSN, CPNP | Pediatrics | Kansas City, MO | $3,484 | 11 |
| , D.O | Pediatrics | Norfolk, VA | $3,331 | 5 |
| , PA-C, MMS | Allergy | San Ramon, CA | $3,063 | 12 |
| , MD | Allergy & Immunology | Marietta, GA | $2,905 | 3 |
| , MD | Pediatric Allergy/Immunology | Kansas City, MO | $2,892 | 2 |
| , M.D | Allergy & Immunology | Tampa, FL | $2,475 | 1 |
Ad
Manufacturing Companies
- AIMMUNE THERAPEUTICS, INC. $8.0M
- Aimmune Therapeutics, Inc. $558,491
- NESTLE HEALTHCARE NUTRITION INC. $40.90
Product Information
- Type Biological
- Total Payments $8.6M
- Total Doctors 2,285
- Transactions 8,076
About PALFORZIA
PALFORZIA is a biological associated with $8.6M in payments to 2,285 healthcare providers, recorded across 8,076 transactions in the CMS Open Payments database. The primary manufacturer is AIMMUNE THERAPEUTICS, INC..
Payment data is available from 2020 to 2024. In 2024, $14,010 was paid across 89 transactions to 88 doctors.
The most common payment nature for PALFORZIA is "Unspecified" ($7.7M, 89.6% of total).
PALFORZIA is associated with 6 research studies, including "A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY" ($5.0M).